BMS’ Opdivo obtains FDA approval for SCLC

It is a great momentum for Bristol-Myers Squibb group: immunotherapy Opdivo (nivolumab) was approved by FDA last Friday for small-cell lung cancer (SCLC) in patients already treated twice, but with no therapeutic benefit. The approval reflects positive clinical results from the CheckMate -032 clinical trial, conducted on 109 patients with SCLC. Opdivo is already approved for non-small-cell lung cancer, thus the new approval means an opportunity for sale increase by at least 10-15%. Bristol-Myers Squibb has exceeded $100bn in capitalization this week.